Mohali’s Dr BR Ambedkar State Institute of Medical Sciences to get 6 bedded ICU soon

Mohali: To ensure that critical patients get the best treatment at nominal charges, Punjab Health and Family Welfare Minister Dr Balbir Singh on Friday announced that Dr BR Ambedkar State Institute of Medical Sciences (AIMS) Mohali is all set to get a 6-bedded medical ICU as a part of the ongoing Sehatmand Punjab Mission. 

During his visit to AIMS Mohali, he stated that Chief Minister Bhagwant Mann will be inaugurating the new ICU facility that will offer advanced medical care to patients at a reasonable price.

Dr Singh said that the ICU is operational and ready to take critical patients with all life-saving equipment like crash carts, patient monitors, defibrillators and infusion pumps along with ventilators.

Also read- PM Modi To Inaugurate 250-Bed IPD At AIIMS Rajkot On February 25

Terming it as a significant milestone in the journey toward advancing healthcare excellence, the Health Minister said that this initiative will strengthen the medical infrastructure of the state.

The Health Minister also visited the newly constructed state-of-the-art Biosafety Level 2 Lab at AIMS Mohali. He said that the purpose of this lab is to cater to the community and help in the timely identification of viruses of public health significance at the molecular level like like influenza virus and other viruses causing respiratory tract infections, vector-borne viruses including dengue, chikungunya, Zika and viruses causing GI infections including hepatitis virus, sexually transmitted infections like Human papillomavirus and viruses causing CNS infections. 

This fully equipped lab has advanced infrastructure and the latest equipment including Biosafety cabinets, RNA extractor, Refrigerated centrifuge, vortex mixers, mini-spinners, thermo-shakers, pipettes, Autoclave, PCR workstations, -40 degree and -80 degree Celsius deep freezers, RTPCR machines, computer units with printers and all the required consumables as reported by the Punjab Newsline.

The health minister accompanied by the director-principal of AIMS Mohali Dr Bhavneet Bharti, Superintendent Dr Navdeep Singh Saini, and SMOs Dr HS Cheema and Dr Vijay Bhagat, assessed the readiness of the ICU.

Punjab Chief Minister Bhagwant Mann, along with his Delhi counterpart Arvind Kejriwal, launched the ambitious ‘Sehatmand Punjab’ Mission worth Rs 550 crore aiming at enhancing the well-being of the people of Punjab and elevating the state’s healthcare infrastructure.

Also read- Punjab Govt Plans To Set Up 2 Medical Colleges In Moga, Khatkar Kalan

Powered by WPeMatico

Health Bulletin 02/ March/ 2024

Here are the Top Health stories for the day:

Court clears hospital and doctor of negligence

The Delhi state consumer disputes redressal commission has absolved Max Super Speciality Hospital, a senior consultant physician & cardio-diabetologist and others in a case alleging medical negligence over the delay in admitting a patient and not providing timely medical treatment resulting in paralysis on the left side of his body and ongoing seizures.

The commission, led by Justice Sangita Dhingra Sehgal delivered the decision on 12th January 2024 noting that the complainant failed to establish negligence or deficiency in service on the part of Max Super Speciality Hospital and no lackadaisical approach of the treating doctors were found.

For more information click on the link below:


Illegal sex determination ring busted

In a significant breakthrough, police teams from Ghaziabad and Sonipat exposed a pre-natal sex determination racket operating within the premises of Shiva Ultrasound, a registered centre in Ghaziabad.

The accused had allegedly been facilitating couples from Haryana and neighbouring states for illicit sex determination tests, charging a hefty fee of Rs 30,000.

For more information click on the link below:

Consignment of spurious drugs worth Rs 43 lakh seized, 2 held

Two people were arrested here on Thursday and a consignment of spurious drugs worth Rs 43 lakh was seized from them by a team of Telangana Police, officials said.
Those arrested include the owner of the factory where the medicines were manufactured, Hyderabad’s Drugs Inspector Kiran Kumar Jannu, who accompanied a four-member Telangana Police team to Kotdwar, told PTI.
For more information click on the link below:

Powered by WPeMatico

Yoga, Blood Pressure Management and Its Evidence from Trials – Dr Indranill Basu Ray

Yoga, a holistic mind-body discipline, is gaining recognition for its role in the management of hypertension (HTN), a widespread health challenge characterized by elevated blood pressure levels. This condition, if left unmanaged, can lead to critical health complications.
The multifaceted approach of yoga, incorporating physical postures, breath control techniques, and meditation, offers a promising avenue for blood pressure (BP) regulation. As a complementary strategy alongside lifestyle changes and medical treatments, yoga offers a non-drug approach to mitigating the risks associated with high blood pressure.
The global health community is increasingly exploring the long-term benefits of yoga as part of a comprehensive strategy for hypertension management, emphasizing the importance of integrating lifestyle modifications for optimal health outcomes.
Research on yoga’s role in managing hypertension reveals its potential as a supportive therapy, capable of lowering both systolic and diastolic blood pressure in individuals with elevated levels.
This body of evidence, encompassing systematic reviews and randomized controlled trials (RCTs), suggests that yoga may offer significant benefits in blood pressure management when implemented alongside standard care or in the absence of other treatments, although its advantages over certain interventions like pharmacotherapy or conventional exercise vary.
The efficacy of yoga in blood pressure reduction appears to depend on the specifics of the yoga practice, with programs that integrate a broader spectrum of yoga elements—such as physical postures, meditation, and breathe control—tending to yield more pronounced benefits.
However, not all studies find yoga to outperform other lifestyle interventions, highlighting the need for further research to clarify its unique contributions to hypertension management.
Yoga’s potential to be incorporated into routine primary healthcare for hypertension has been demonstrated, particularly through interventions led by health professionals. These programs have shown success in reducing blood pressure, suggesting a practical model for yoga’s integration into broader health strategies.
The physiological mechanisms underlying yoga’s impact on blood pressure involve the modulation of stress responses, enhancement of parasympathetic nervous system activity, and adjustments in baroreceptor sensitivity. Evidence points towards the calming effect of yoga on the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis as key factors in its efficacy.
Despite the heterogeneity in yoga practices and the varying quality of research, there is a consensus that yoga can be beneficial for both normotensive and hypertensive individuals.
Yet, due to this variability, specific yoga recommendations for hypertension treatment remain to be determined.
Yoga interventions that emphasize breathing and meditation, especially when practiced regularly, are linked with greater reductions in blood pressure. Such practices, particularly Hatha yoga, have been found beneficial across different age groups, with meditation showing notable effectiveness in older adults and yoga in younger populations.
Beyond blood pressure control, yoga has been associated with improvements in other cardiovascular health markers, mental health, and overall quality of life, underscoring its value as a multifaceted intervention for hypertension.
Notably, yoga therapy, when combined with dietary changes or biofeedback, has demonstrated enhanced effectiveness, further supporting its role as a comprehensive and complementary treatment option without adverse effects.
Yoga presents a promising adjunct therapy for hypertension, characterized by its ability to lower blood pressure and improve general health, the need for more rigorous and conclusive research remains to delineate its full potential and optimal application in hypertension care.
The compilation of studies suggests yoga as an effective supplementary approach for blood pressure reduction among individuals with hypertension. It appears that the most significant advantages are linked to a holistic yoga regimen that incorporates physical postures, breathing techniques, and meditation or mental relaxation, especially with regular practice.
Despite supportive evidence for yoga’s role in lowering blood pressure, there remains a need for further high-caliber research to identify the yoga practices most beneficial for hypertension care.
Yoga offers a non-medical strategy for hypertension management, with research indicating its potential in decreasing both systolic and diastolic blood pressure levels. The integration of breathing exercises and meditation/mental relaxation within yoga routines may amplify its anti-hypertensive benefits.
While practicing yoga alone has its merits, augmenting it with additional lifestyle adjustments, such as improved nutrition, can lead to more substantial reductions in blood pressure. Current research advocates for incorporating yoga into clinical hypertension treatment guidelines, promoting a comprehensive approach that emphasizes treating the individual holistically.

Disclaimer: The views expressed in this article are of the author and not of Medical Dialogues. The Editorial/Content team of Medical Dialogues has not contributed to the writing/editing/packaging of this article.

Powered by WPeMatico

An overgrowth of nerve cells appears to cause lingering symptoms after recurrent UTIs

A perplexing problem for people with recurring urinary tract infections (UTIs) is persistent pain, even after antibiotics have successfully cleared the bacteria.

Powered by WPeMatico

Large-scale study explores link between smoking and DNA changes across six racial and ethnic groups

Smoking changes the way genes are expressed, which later contributes to the development of lung cancer and other smoking-related illnesses. But the link between epigenetics (the study of mechanisms that impact gene expression) and smoking is not fully understood, especially in terms of differences across racial and ethnic groups.

Powered by WPeMatico

Less chemoradiation is possible for some cancer patients

According to a new study from experts at the University of Michigan Health Rogel Cancer Center, some oropharynx cancer patients may qualify for less radiation treatments. This could assist many patients in a quicker return to their normal lives.

Powered by WPeMatico

America’s biggest pharmacy chains announce abortion pill rollout

America’s two biggest pharmacy chains said Friday they will begin dispensing prescription abortion pills in a limited number of states where it’s legal.

Powered by WPeMatico

COVID-19 no longer means five days in isolation, CDC says

Americans who test positive for COVID-19 no longer need to stay in isolation for five days, U.S. health officials announced Friday.

Powered by WPeMatico

FDA approves Exblifep for complicated UTI including pyelonephritis

The US Food and Drug Administration (FDA) has approved Exblifep® (cefepime/enmetazobactam) for treatment of complicated urinary tract infections (cUTIs), including pyelonephritis among patients 18 years of age and older.

Allecra has also received a five-year marketing exclusivity extension from the FDA as part of the Generating Antibiotic Incentives Now Act (GAIN Act). The GAIN Act, enacted by the U.S. Congress, incentivizes the creation of new anti-infective therapeutics by providing benefits to manufacturers of Qualified Infectious Disease Products (QIDPs).

“Receiving FDA approval is a tremendous achievement for Allecra and a testament to the hard work and dedication of a small, yet highly focused team of individuals. I extend my sincere congratulations to my colleagues Omar Lahlou and Patrick Velicitat for their leadership and oversight throughout this whole process,” said Iain Buchanan, Supervisory Board Member of Allecra Therapeutics. “As we continue our discussions with strategic partners for product launch in the U.S., we value the FDA’s positive decision on EXBLIFEP®’s ability to address a critical unmet medical need for patients.”

The FDA’s approval of EXBLIFEP® was supported by a totality of clinical data that demonstrated EXBLIFEP® effectiveness against antimicrobial resistance in gram-negative bacteria, especially resistance mediated by both ESBL (Extended Spectrum Beta Lactamases) and AmpC. This included results from Allecra’s Phase 3 ALLIUM trial, which met criteria for non-inferiority and superiority compared to piperacillin/tazobactam in the primary composite outcome of clinical cure and microbiological eradication in patients with cUTIs.

Allecra is the sole holder of a significant patent estate covering EXBLIFEP® in major territories with the GAIN Act extending Allecra’s market exclusivity until 2032. Enmetazobactam was first discovered by Orchid Pharma and all rights outside India were assigned to Allecra Therapeutics in 2013. The company has since taken the sole responsibility for the international clinical and regulatory development of EXBLIFEP®. Allecra was founded through a strategic partnership formed by Nicholas Benedict, Stuart Shapiro and Edward Currie in conjunction with Orchid Chemicals and Pharmaceuticals Ltd. and Allecra lead investors, Andera Partners, Forbion and EMBL Ventures. The company has concluded exclusive license agreements for EXBLIFEP® with Shanghai Haini Pharmaceutical in Greater China and ADVANZ PHARMA in Europe.

About EXBLIFEP® (cefepime/enmetazobactam)

EXBLIFEP® (cefepime/enmetazobactam) has been investigated in patients with complicated urinary tract infections (cUTIs) compared to piperacillin/tazobactam, a current standard of care, in a randomized, controlled, double-blind, global Phase 3 trial. EXBLIFEP® has already been submitted for Marketing Authorization Approval in Europe by Allecra’s commercial partner, Advanz Pharma. The European Medicines Agency (EMA) has indicated that, in light of results obtained in an epithelial lining fluid penetration study, the company is eligible for approval of cefepime/enmetazobactam for use in hospital-acquired/ventilator-associated bacterial pneumonia. A positive opinion was received from the CHMP (The Committee for Medicinal Products for Human Use) in January 2024.

Powered by WPeMatico

Robot-Assisted Pancreatoduodenectomy Shows Short-Term Benefits in Chinese Trial

A recent open-label randomized trial conducted in China assessed the feasibility and safety of robot-assisted pancreatoduodenectomy compared to open surgery for pancreatic head or periampullary tumors. The study aimed to evaluate short-term outcomes, including postoperative hospital length of stay, operating times, blood loss, and complications. The study was published in the journal Lancet Gastroenterology and Hematology by Prof Qu Liu and colleagues.

Pancreatoduodenectomy is a complex surgical procedure commonly used to treat pancreatic and periampullary tumors. Robot-assisted surgery has gained attention as a potential alternative to open surgery, offering potential advantages such as shorter hospital stays and reduced blood loss. However, conclusive evidence regarding its efficacy and safety compared to traditional open surgery has been limited.

The multicenter trial involved 164 patients randomly assigned to either robot-assisted or open pancreatoduodenectomy. Highly experienced surgeons performed the procedures, with five surgeons from high-volume hospitals participating. The study evaluated short-term outcomes, including postoperative hospital length of stay, operating times, blood loss, complications, readmission rates, and mortality.

Key Findings:

  • Robot-assisted pancreatoduodenectomy significantly reduced postoperative hospital length of stay compared to open surgery (median 11 vs. 13.5 days).

  • Robot-assisted surgery also demonstrated shorter operating times (245 vs. 298 minutes) and reduced blood loss (75 vs. 150 mL).

  • Complication rates, readmission rates, and mortality were similar between the two groups.

  • Pathology outcomes, including tumor characteristics, were comparable between the robotic and open surgery groups.

The trial concluded that robot-assisted pancreatoduodenectomy is feasible and safe, with modest improvements in short-term outcomes compared to open surgery. While the study focused on short-term benefits, the long-term oncological outcomes require further investigation.

Despite the promising results, the generalizability of the findings may be limited, and the clinical benefit of robot-assisted surgery should be carefully weighed against the associated costs. Future research should prioritize assessing long-term oncological outcomes and maintaining comprehensive registries for outcome tracking in robot-assisted pancreatoduodenectomy.

Reference:

Liu Q, et al “Effect of robotic versus open pancreaticoduodenectomy on postoperative length of hospital stay and complications for pancreatic head or periampullary tumours: a multicentre, open-label randomised controlled trial” Lancet Gastroenterol Hepatol 2024; DOI: 10.1016/S2468-1253(24)00005-0. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00005-0/abstract

Powered by WPeMatico